New tablet manufacturing facility in Kazakhstan

On 8 September, in Shymkent located in the south of Kazakhstan, a new facility for the manufacture of solid oral drug forms was officially opened as part of celebrations of the 135th anniversary of SANTO. The new facility will have production capacity of more than 200 million of tablets and capsules annually. It is yet another successfully completed phase of the largest investment programme in Kazakh pharmaceutical industry, which has been implemented since 2011 by the Polpharmа Group as an investor.

The official opening ceremony was attended by SANTO main shareholders (the company’s trading name is Chimpharm), representatives of Polish and Kazakh governments, local authorities, contractors and partners.

The new facility was developed in line with the requirements of Good Manufacturing Practice (GMP) regarding the manufacture of medicinal products. The production line was equipped with state-of-the-art devices and the staff was trained in other manufacturing facilities of the Polpharmа Group.

The completion of USD 13.5-million-worth solid forms facility is an important part of the investment project implemented at the Shymkent site. The total value of investments planned for completion by 2020 exceeds USD 108 million of which USD 70 million has already been expended. In addition, the value of technologies provided, necessary trainings and knowledge transfer is estimated at almost PLN 40 million. 

Favourable investment climate and participation in public contracts enabled Polpharmа Group to implement the largest investment in the history of Kazakh pharmaceutical industry. So far, we launched a new ampoule drugs manufacturing department, manufacturing of solutions for infusion and two lines for the manufacture of powdered antibiotics. We also modernised the finished products warehouse, R&D centre, quality control laboratories and infrastructure and erected a new boiler room.

The new production area was opened on the 135th anniversary of the Shymkent facility to serve as a symbol of new perspectives opened ahead of the largest local pharmaceutical company in Kazakhstan. SANTO (Chimpharm) has been one of the largest-operating drug manufacturers in the Eurasian Economic Union. The facility was established in 1882. In 2011, it was acquired by the Polpharmа Group and was thoroughly modernised.

“SANTO has gone a long way over the years: from a small facility making Santonin based on local herbs through to one of the leading pharmaceutical companies in Kazakhstan, offering advanced products based on innovative technologies. I am happy to be part of this success as an investor, entrepreneur and a friend of Kazakhstan,” said Jerzy Starak, Chairman of the Supervisory Board of Polpharma and member of the Foreign Investors Council established by the President of Kazakhstan.

Currently, SANTO makes every third drug delivered to healthcare facilities in Kazakhstan as part of the public free healthcare system. The company’s production capacity is 1.2 billion tablets, capsules and granules, 300 million ampoules, 48 million antibiotic vials, 24 million syrup bottles, 6 million sachets and infusion liquid packs annually. SANTO is the second-largest pharmaceutical company operating in Kazakhstan, with a portfolio of more than 200 drugs in 12 therapeutic areas. The company has more than 1,000 employees at the Shymkent site and in all regions of the Republic of Kazakhstan. SANTO is growing its exports to countries such as Turkmenistan, Kyrgyzstan, Mongolia, Tajikistan, Russia and Ukraine.